NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Core Insights - NeuroSense Therapeutics is presenting new clinical data from its Phase 2b trial of PrimeC, a novel therapy for amyotrophic lateral sclerosis (ALS), at the 77th Annual American Academy of Neurology Meeting [1][2][3] Company Overview - NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease [7][8] - The company aims to address significant unmet medical needs in neurodegenerative diseases, which currently have limited effective therapeutic options [8] Product Information - PrimeC is NeuroSense's lead drug candidate, an extended-release oral formulation combining two FDA-approved drugs: ciprofloxacin and celecoxib [6] - The therapy targets multiple mechanisms contributing to ALS, including motor neuron degeneration, inflammation, iron accumulation, and impaired RNA regulation [6] - PrimeC has shown safety and efficacy in a Phase 2a clinical trial, with significant changes in ALS-related biological markers indicating its biological activity [6] Clinical Trial Insights - The Phase 2b trial data presented by Jeremy Shefner, M.D., Ph.D., indicates PrimeC's potential to redefine ALS treatment by demonstrating safety, tolerability, and a marked reduction in ALS progression [2][3] - Jeffrey Rosenfeld, M.D., Ph.D., will discuss the role of microRNA modulation in ALS treatment, highlighting PrimeC's multi-targeted approach [3][4] - The anticipation for the forthcoming Phase 3 trial of PrimeC is heightened due to significant changes in relevant biomarker endpoints reflecting target engagement [4] ALS Disease Context - ALS is an incurable neurodegenerative disease that leads to complete paralysis and death within 2-5 years from diagnosis, with over 5,000 new cases diagnosed annually in the U.S. [5] - The annual disease burden of ALS in the U.S. is approximately $1 billion, and the number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU [5]